Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468931 | 1.00 | LOXL2 (0.42) | LOXL2CCNCCDK8GRIN2DGRIN3B | |
| SCHEMBL6069584 | 0.80 | CCNT1 (0.42) | LOXL2ALDH1A1LMNA | |
| SCHEMBL15786313 | 0.80 | LOXL2 (0.38) | LOXL2ALDH1A1NUDT1LMNAAPOBEC3G | |
| SCHEMBL6069581 | 0.80 | CCNT1 (0.42) | LOXL2ALDH1A1LMNA | |
| SCHEMBL9768963 | 0.76 | EP300 (0.36) | CCNCCDK8ALDH1A1LMNA | |
| SCHEMBL19840144 | 0.76 | LOXL2 (0.35) | LOXL2 | |
| SCHEMBL19840136 | 0.76 | LOXL2 (0.35) | LOXL2 | |
| SCHEMBL25860651 | 0.73 | GAA (0.43) | ALDH1A1LMNA | |
| SCHEMBL23457261 | 0.72 | — | — | |
| SCHEMBL12530511 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103328471-A | Method of making azaindazole derivatives | TAKEDA PHARMACEUTICAL | 2013-09-25 | — | — | CN | disclosed |
| EP-2627654-A1 | METHOD OF MAKING AZAINDAZOLE DERIVATIVES | Takeda California, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130197229-A1 | METHOD OF MAKING AZAINDAZOLE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012051450-A1 | METHOD OF MAKING AZAINDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197229-A1 | METHOD OF MAKING AZAINDAZOLE DERIVATIVES | GCK, GALK1, GCKR | LOXL2 4084/4885CCNC 4720/4885CDK8 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.